Abivax SA, a prominent biotechnology company headquartered in Paris, France, continues to make significant strides in the healthcare sector, particularly in the development of anti-viral therapies and therapeutic vaccines. As of August 11, 2026, the company’s stock closed at 109.3 EUR on the NYSE Euronext Paris, with a market capitalization of 9.46 billion EUR. Despite a challenging financial landscape reflected by a price-to-earnings ratio of -24.27, Abivax SA remains committed to its mission of addressing infectious diseases in Asia and Latin America.
The company’s flagship product, ABX 464, is currently in Phase II clinical trials. This therapeutic aims to provide sustained viral remission or a functional cure for patients with HIV/AIDS, marking a significant advancement in the treatment of this global health challenge. Additionally, ABX 203, a therapeutic vaccine candidate, is progressing through Phase IIb/III trials for the treatment of chronic hepatitis B, showcasing Abivax SA’s dedication to combating viral infections.
ABX 196, another notable product, is an art immune enhancer candidate that has successfully completed Phase I clinical trials for iNKT cells. This development underscores the company’s innovative approach to enhancing immune responses. Furthermore, Abivax SA is actively developing vaccines targeting typhoid, meningitis B and C, and leptospirosis, expanding its portfolio to address a broader range of infectious diseases.
In its pre-clinical programs, Abivax SA is exploring new frontiers with ABX 220, aimed at treating Dengue fever, and ABX 544, a drug candidate for Ebola based on polyclonal antibodies. Additionally, ABX 311 is being developed for the treatment of Chikungunya, further demonstrating the company’s commitment to addressing emerging infectious threats.
Abivax SA’s collaborative efforts are evident through its license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Moreover, the company has established a partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia, highlighting its international reach and collaborative spirit.
Incorporated in 2013, Abivax SA continues to be a key player in the biotechnology industry, leveraging its expertise and partnerships to advance the development of innovative therapies and vaccines. For more information, stakeholders and interested parties can visit the company’s official website at www.abivax.com .
